Home / Encyclopedia / Khavinson Bioregulators / Prostamax

MONOGRAPH No. 058

EVIDENCE BASEPreclinical

TYPE

Natural peptide complex (cytomedin)

SEQUENCE

Proprietary complex

CAS

Not assigned

EU STATUS

Research only

WADA

Not listed

MIN PURITY

Lab-specific

Khavinson Bioregulators

Prostamax — EU research guide.

Prostamax is a Khavinson-series peptide bioregulator derived from prostate gland tissue, proposed to support prostate cell function and regulate local inflammatory responses. It is one of several organ-specific cytomedin-style bioregulators in the same research family as Chitomur and Testagen.

Last reviewed: 2026-09-24

What is Prostamax?

What does the research show?

No human study of Prostamax itself could be verified; the human studies of Eastern European groups with prostate-derived products concern extract preparations such as Prostatilen and Vitaprost, not Prostamax, and data on Prostamax are preclinical or computational. No independently replicated controlled human trials are publicly available as of mid-2026.

EU legal status

Not approved as a medicine anywhere in the EU. Sold by a small number of specialist research vendors for laboratory research only.

⚠ Should not be treated as a substitute for established prostate health screening or care — this is an unproven laboratory research compound with a narrow evidence base.

✓ Not yet tracked in PeptideCompare's price comparison. Verify any vendor's COA and sequence/identity claims directly before ordering — see our COA guide.

EVIDENCE SUMMARY

ANIMAL ONLY

Tetrapeptide KEDP: toxicity and tissue-culture data (patent) — A 2002 patent from the St Petersburg institute describes Lys-Glu-Asp-Pro as a prostate-regulating tetrapeptide. It reports acute, 90-day and 6-month toxicity tests in mice and rats with no pathological changes, cultured chick-embryo tissue explants (45 samples) with a 23% higher growth index at one tested concentration, and a chronic prostatitis model in 41 rats. This is self-reported patent material, not a peer-reviewed paper.

NO HUMAN DATA

No human study of the synthetic tetrapeptide found — No clinical study of KEDP itself was located. Human reports in the Russian literature mainly concern prostate-extract preparations such as Prostatilen and Vitaprost, which are different, non-synthetic products and cannot be transferred to this tetrapeptide.

LIMITED

Proposed mechanism: DNA binding (in silico only) — A 2016 paper from the Khavinson group lists Prostamax as the tetrapeptide Lys-Glu-Asp-Pro and predicts, by molecular docking, strong binding (roughly -4 to -4.5 kcal/mol) to a complementary DNA sequence. This is a computational model, not an experimental result.

Molecular information

CAS number

Not assigned

Pharmacokinetics

No established human pharmacokinetic data. Published human PK parameters for this compound are not available; reported data are limited to animal models or absent. No curve is shown, to avoid implying data that does not exist.

Potency retained over time

Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.

Freezer −20 °C

36+ mo

Stable · >95% potency

Fridge 4 °C

3-4 mo

In use · after recon

Room 20 °C

2-3 wks

Limited · moderate loss

Warm 37 °C+

2-3 days

Critical · rapid degradation

⚠ A structural estimate, derived from each compound's sequence length, cyclisation and oxidation-, deamidation- and light-sensitive residues. Indicative only — not lab-measured per batch.

Prostamax is not yet in our price comparison

We expand EU supplier coverage every month.

References

Patent by the developing institute, the only source found that describes the KEDP tetrapeptide with experimental data. The results are self-reported and were not peer-reviewed; the patent text available did not give the outcome of the prostatitis model. Khavinson VKh, Malinin VV, Grigoriev EI. Tetrapeptide regulating prostate function, pharmacological agent based thereon and method of its use. Russian patent RU 2177802 C1, published 10 January 2002. St Petersburg Institute of Bioregulation and Gerontology. Source
Modelling paper by the Khavinson group that ties the name Prostamax to the sequence Lys-Glu-Asp-Pro. It is a docking prediction only, with no laboratory or clinical data on Prostamax. Khavinson VKh, Lin'kova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. DOI

Prostamax — EU research guide.

What is Prostamax?

What does the research show?

EU legal status

Molecular information

Pharmacokinetics

Potency retained over time

Prostamax is not yet in our price comparison

References

Related guides

Bolamin

Bronchogen

Cardiogen